ADM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Archer-Daniels-Midland Co is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. The stock's recent negative price trend, declining financial performance, and mixed analyst sentiment suggest a cautious approach. While there are potential positive catalysts in the biofuel sector, they are not strong enough to outweigh the current challenges.
The stock's MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 34.185, not signaling oversold or overbought conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near key support levels at S1: 66.325, with resistance at R1: 69.839. Overall, the technical indicators suggest a mixed trend.
The EPA's proposed reallocation of biofuel blending obligations and potential increase in biofuel demand could benefit ADM's biofuel-related operations in the long term.
Declining revenue (-13.68% YoY), net income (-19.58% YoY), and EPS (-20.34% YoY) in Q4 2025 highlight financial struggles. Analyst ratings remain cautious, with several firms maintaining neutral or underperform ratings and only modest price target increases. The stock's recent price decline (-1.03% regular market, -0.59% post-market) and lack of significant insider or hedge fund activity further dampen sentiment.
In Q4 2025, ADM reported a significant drop in revenue, net income, and EPS, reflecting a challenging operating environment. Gross margin improved slightly to 6.54%, but this is insufficient to offset the broader financial decline.
Analysts have mixed views on ADM. Recent price target increases are modest, with Barclays raising the target to $68 and BMO Capital to $63, while Morgan Stanley downgraded the stock to Underweight with a $50 target. Concerns about weaker margins and limited EPS growth persist.
